4D Molecular Therapeutics (NASDAQ:FDMT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday, Zacks.com reports.
According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California. “
Shares of NASDAQ FDMT traded up $0.07 during midday trading on Thursday, reaching $27.46. The stock had a trading volume of 63,246 shares, compared to its average volume of 150,567. 4D Molecular Therapeutics has a 12-month low of $25.72 and a 12-month high of $55.11. The business’s 50-day simple moving average is $34.82.
4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Wednesday, May 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.10) by $0.49. On average, sell-side analysts expect that 4D Molecular Therapeutics will post -1.89 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth $31,000. Citigroup Inc. purchased a new position in 4D Molecular Therapeutics during the first quarter valued at $59,000. Strs Ohio bought a new stake in 4D Molecular Therapeutics in the 1st quarter valued at $82,000. Davidson Kempner Capital Management LP purchased a new stake in 4D Molecular Therapeutics in the 4th quarter worth $124,000. Finally, New York State Common Retirement Fund bought a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at about $152,000.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
Featured Article: Stock Symbol
Get a free copy of the Zacks research report on 4D Molecular Therapeutics (FDMT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com